** Alvotech ALVO.O up 5.4% and US shares of Teva Pharmaceuticals TEVA.TA dipping 1.2% on Fri after the partner cos said they launched a biosimilar to Johnson & Johnson's JNJ.N Stelara in the US
** Launch marks the second biosimilar to blockbuster autoimmune drug Stelara following Amgen's AMGN.O Wezlana in Jan, with Biocon Biologics BIOC.NS and Fresenius Kabi FRES.M3 expected to follow soon ** UBS analyst sees launch as a success path for future biosimilars; forecasts global sales of $390 mln by 2028 ** ALVO's stock has fallen about 7% YTD, while TEVA is down 24%
(Reporting by Noel Randewich)
((noel.randewich@tr.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。